DS-2243
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 18, 2026
DS-2243a, an HLA-A*02/NY-ESO-directed bispecific T‑cell engager, shows potent anti-tumor activity in preclinical models of solid tumors
(AACR 2026)
- P1 | "Preclinical data indicate that DS-2243a has strong potential to deliver clinically meaningful anti-tumor activity in patients with HLA-A*02 and NY-ESO-expressing cancers. The first-in-human study DS2243-054 (NCT06644755) is being conducted to evaluate DS-2243a monotherapy in patients with advanced or metastatic solid tumors."
Bispecific • First-in-human • IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CTAG1B • CTAG2 • HLA-A
April 23, 2025
A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T‑cell engager, in patients with advanced solid tumors.
(ASCO 2025)
- P1 | "Secondary outcome measures include ORR (dose escalation only), time to response, duration of response, progression-free survival (all assessed by the investigator per RECIST 1.1), and overall survival. The planned sample size is ~150 patients; enrollment is ongoing."
Clinical • Metastases • P1 data • Liposarcoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Synovial Sarcoma • Urothelial Cancer • CTAG1B • CTAG2 • HLA-A
November 22, 2024
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=150 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Urothelial Cancer
1 to 3
Of
3
Go to page
1